Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Subscribe To Our Newsletter & Stay Updated
